The significance of intrinsic antibacterial activity of sulbactam and tazobactam for susceptibility testing of inhibitor-protected penicillins;Bedeutung der antibakteriellen eigen-aktivität von sulbactam und tazobactam für die empfindlichkeitsprüfung von inhibitor- geschützten penicillinen

Chemotherapie Journal

Volumn 13, Issue 6, 2004, Pages 238-241

  Grimm, Heinz ^a,b   Funke, Guido ^a,b  

^a Inst F Medizinische Mikrobiologie ^*

^b Inst fur Medizinische Mikrobiologie   (Germany)

Author keywords

Beta lactamantibiotics; Methods; Sulbactam; Susceptibility testing; Tazobactam

Indexed keywords

BETA LACTAMASE INHIBITOR; PENICILLIN G; PIPERACILLIN; SULBACTAM; TAZOBACTAM;

ANALYTIC METHOD; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; DRUG EFFECT; DRUG SENSITIVITY; ENTEROBACTERIACEAE; ENZYME INHIBITION; HUMAN; MINIMUM INHIBITORY CONCENTRATION;

EID: 10844232945     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Adam D. Klinische Studien mit Tazobactam/Piperacillin - Eine Übersicht. In: Adam D, Stille W (editors). Tazobactam/Piperacillin. FAC 11-4. Fortschr Antimikrob Antineoplast Chemother. München: Futuramed Verlag, 1992:467-73.
2. Aldridge KE, Morice N, Schiro DD. Increased in vitro activity of ceftriaxone by addition of tazobactam against clinical isolates of anaerobes. Diagn Microbiol Infect Dis 1994;19:227-34.
3. Aswapokee N. Neu HC. A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor. J Antibiot 1978;31:1238-44.
4. Caine VA, Foulds G, Handsfield HH. Therapeutic trial and pharmacokinetics of sulbactam for uncomplicated gonorrhea in men. Antimicrob Agents Chemother 1984;26:683-5.
5. Crosby MA, Gump DW. Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. Correlated with beta-lactamase production, Antimicrob Agents Chemother 1982;22:398-405.
6. Deutsches Institut für Normung e.V. Methoden zur Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern (außer Mykobakterien) gegen Chemotherapeutika. Teil 6: Bestimmung der minimalen Hemmkonzentration nach der Agar-Dilutionsmethode. DIN 58940-6. Berlin: Beuth Verlag, 1989.
7. Deutsches Institut für Normung e.V. Methoden zur Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika. Teil 4: Bewertungsstufen der minimalen Hemmkonzentration - MHK-Grenzwerte von antibakteriellen Wirkstoffen. DIN 58940-4, Beiblatt I. Berlin: Beuth Verlag, 2000.
8. Duez JM, Cordin X, Pechinot A, Siebor E, et al. Activité synergique in vitro de l'association piperacilline-tazobactam vis-à-vis d'enterobacteries resistantes aux betalactamines. Pathol Biol 1991;39:374-378.
9. Grimm H. Bakteriologische In-vitro-Untersuchungen zur Kombination von Betalaktam-Antibiotika. In: Stille W, Elsser R (Hrsg.). Kombinationen von Betalaktam-Antibiotika: Arbeitstagung der Sekt. Antimikrobielle Chemotherapie der Paul-Ehrlich-Ges., Frankfurt, 13. März 1981. München: Zuckschwerdt, 1981:26-34.
10. Grimm H, Blessing J, Funke G. In-vitro-Aktivität von Piperacillin in Kombination mit Tazobactam sowie mit Sulbactam gegen Piperacillin-nicht- sensible Enterobacteriaceae. Chemother J 2003;12:174-7.
11. Horii T, Kimura T, Sato-Kawamura K, Nada T, et al. Beta-lactamase inhibitors have antibacterial activities against Helicobacter pylori. J Infect Chemother 1999;5:206-7.
12. Jolivet-Gougeon A. Buffet A, Dupuy C, Sixou JL, et al. In vitro susceptibilities of Capnocytophaga isolates to beta-lactam antibiotics and beta-lactamase inhibitors. Antimicrob Agents Chemother 2000;44:3186-8.
13. Joly-Guillou ML, Deere D, Herrman JL, Bourdelier E, et al. Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. J Antimicrob Chemother 1995;36:619-29.
14. Jones RN, Barry AL. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination. J Clin Microbiol 1987;25:1920-5.
15. Jones RN, Barry AL. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Diagn Microbiol Infect Dis 1989;12:495-510.
16. Kazmierczak A, Pechinot A, Siebor E, Cordin X, et al. Sulbactam: secondary mechanisms of action. Diagn Microbiol Infect Dis 1989;12: 1395-465.
17. Klastersky J, Van der Auwera P. In vitro activity of sulbactam in combination with various beta-lactam antibiotics. Diagn Microbiol Infect Dis 1989;12:165S-9S.
18. Lees L, Milson JA, Knirsch AK, Greenhalgh K. Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use. Rev Infect Dis 1986;8(Suppl. 5): S644-50.
19. Moosdeen F, Williams JD, Yamabe S. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam. Antimicrob Agents Chemother 1988;32:925-7.
20. NCCLS. Performance standards for antimicrobial susceptibility testing; twelfth informational supplement. NCCLS document M100-S12. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania USA, 2002.
21. Nord CE, Dornbusch K, Olsson B. Studies on beta-lactamase in Bacteroides fragilis. Infection 1980;8(Suppl. 2):S167-70.
22. Obana Y, Nishino T. In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus. J Antimicrob Chemother 1990;26:677-82.
23. Pfaller MA, Barry AL, Fuchs PC, Gerlach EH, et al. Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam. Eur J Clin Microbiol Infect Dis 1992;11:728-32.
24. Pfaller MA, Barry AL, Fuchs PC, Gerlach EH, et al. Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam. Eur J Clin Microbiol Infect Dis 1993;12:356-62.
25. Retsema JA, English AR, Girard AE, Anderson M, et al. Sulbactam and ampicillin: synergistic antibacterial activity against hospital isolates of Enterobacteriaceae, methicillin-resistant Staphylococcus, and anaerobes. Presented at the 13th International Congress of Chemotherapy, Vienna, 28 Aug - 2 Sept 1983 (WO 59, part 23).
26. Shah PM. Therapie mit Betalaktam-Kombinationen. In: Stille W, Elsser R (Hrsg.). Kombinationen von Betalaktam-Antibiotika: Arbeitstagung der Sekt. Antimikrobielle Chemotherapie der Paul-Ehrlich-Ges., Frankfurt, 13.März 1981. München: Zuckschwerdt, 1981:86-90.
27. Strayer AH, Gilbert DH, Pivarnik P, Medeiros AA, et al. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and - susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother 1994;38:2351-6.
28. Suh B, Shapiro T, Jones R, Satishchandran V, et al. In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species. Diagn Microbiol Infect Dis 1995;21: 111-4.
29. Traub WH, Spohr M. Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, Genospecies 3, and Genospecies 6). Antimicrob Agents Chemother 1989;33:1617-9.
30. Wise R, Andrews JM, Bedford KA. Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother 1980;6:197-206.